Literature DB >> 2054937

Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors.

Y J Xu1, V Gopalakrishnan.   

Abstract

Radioligand binding studies of the cardiac arginine vasopressin (AVP) receptor, together with studies on the AVP-evoked alterations in the [Ca2+]i levels, were undertaken using primary cultures of neonatal rat cardiomyocytes. Rapid, reversible, specific, high-affinity and low-capacity binding sites were detected for the agonist, [3H]AVP, and the V1 selective antagonist, d(CH2)5 Tyr (Me)-[3H]AVP (V1 antagonist), radioligands. The V2 selective antagonist radioligand, d(CH2)5 D-Ile des-Gly NH2-[3H]AVP, showed very little binding even at very high concentrations. [3H]AVP and [3H]V1 antagonist specific binding attained equilibrium in 10 minutes at 37 degrees C. The Kd and Bmax values (mean +/- SEM) were [3H]AVP: Kd 1.44 +/- 0.18 nM; Bmax 5,253 +/- 590 sites/cell; [3H]V1 antagonist: Kd 0.96 +/- 0.10 nM; Bmax 6,869 +/- 485 sites/cell. Ki values for a series of AVP-related peptide analogues and antagonists determined by competitive inhibition of [3H]AVP binding were consistent with the saturation data. The results suggest that these cells possess a homogeneous population of V1 subtype AVP receptors. AVP increased [Ca2+]i in a concentration-dependent manner as judged by fura-2 fluorescence. This was completely attenuated by inclusion of the V1 antagonist. The maximal increase in [Ca2+]i evoked by AVP from a resting level of 60 +/- 5 nM was less (250 +/- 35 nM) in comparison to the maximal response evoked by angiotensin II (2,337 +/- 640 nM).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2054937     DOI: 10.1161/01.res.69.1.239

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  19 in total

1.  Fura-2 fluorescent technique for the assessment of Ca2+ homeostasis in cardiomyocytes.

Authors:  Y J Xu; Q Shao; N S Dhalla
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

2.  Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy.

Authors:  T Taigen; L J De Windt; H W Lim; J D Molkentin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 3.  The role of neuropeptides in adverse myocardial remodeling and heart failure.

Authors:  Alexander Widiapradja; Prasad Chunduri; Scott P Levick
Journal:  Cell Mol Life Sci       Date:  2017-01-17       Impact factor: 9.261

4.  Vasopressin accelerates protein synthesis in neonatal rat cardiomyocytes.

Authors:  Y Xu; R L Hopfner; J R McNeill; V Gopalakrishnan
Journal:  Mol Cell Biochem       Date:  1999-05       Impact factor: 3.396

5.  Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor.

Authors:  J Fukuzawa; T Haneda; K Kikuchi
Journal:  Mol Cell Biochem       Date:  1999-05       Impact factor: 3.396

Review 6.  Significance of hyponatremia in heart failure.

Authors:  Luca Bettari; Mona Fiuzat; Gary M Felker; Christopher M O'Connor
Journal:  Heart Fail Rev       Date:  2012-01       Impact factor: 4.214

Review 7.  Management of vasodilatory shock: defining the role of arginine vasopressin.

Authors:  Martin W Dunser; Volker Wenzel; Andreas J Mayr; Walter R Hasibeder
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 8.  Role of vasopressin in the management of septic shock.

Authors:  Gökhan M Mutlu; Phillip Factor
Journal:  Intensive Care Med       Date:  2004-04-21       Impact factor: 17.440

Review 9.  Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.

Authors:  Navneet S Rehsia; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

Review 10.  Vasopressin receptor antagonists: from pivotal trials to current practice.

Authors:  Ankur Kalra; Valmiki Maharaj; Steven R Goldsmith
Journal:  Curr Heart Fail Rep       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.